Effects of dexamethasone treatment on serous retinal detachment in ranibizumab-resistant diabetic macular edema

dc.authorid0000-0003-1827-968X
dc.contributor.authorBayat, Alper Halil
dc.contributor.authorElçioğlu, Mustafa Nuri
dc.date.accessioned2020-12-11T07:02:09Z
dc.date.available2020-12-11T07:02:09Z
dc.date.issued2020
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalı
dc.description.abstractPurpose: To evaluate outcome of intravitreal dexamethasone implant (IDI) treatment on serous retinal detachment (SRD) in patients with ranibizumab-resistant diabetic macular edema (DME).Materials and methods: Forty-eight eyes of 48 patients with DME resistant to ranibizumab were enrolled in this retrospective and comparative study. Patients were divided into two groups according to presence of serous retinal detachment: (1) SRD or (2) non-SRD groups. All patients had at least three monthly ranibizumab injections, after which they were treated with IDI. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), use of antiglaucomatous drugs, and presence of cataract progression were noted at 1, 3, and 6 months post-IDI treatment.Results: There was not any statistically significant difference in terms of baseline characteristics of the patients. The mean CRT was declined in both groups at 1, 3, and 6 months (p < 0.001). After IDI treatment, the mean BCVA was improved in both groups at 1, 3, and 6 months (p < 0.001). When groups were compared, the change in CRT was higher in the SRD group (p = 0.018), while there was no statistically significant difference between groups in terms of BCVA changes (p = 0.448).Conclusion: The presence of SRD resulted in higher anatomical gain. SRD had no effects on visual changes after dexamethasone treatment in patients with ranibizumab-resistant DME.
dc.identifier.citationBayat, A. H. ve Elçioğlu, M. N. (2020). Effects of dexamethasone treatment on serous retinal detachment in ranibizumab-resistant diabetic macular edema. Therapeutic Advances in Ophthalmology, 12. https://dx.doi.org/10.1177/2515841420971936
dc.identifier.doi10.1177/2515841420971936
dc.identifier.issn2515-8414
dc.identifier.urihttps://dx.doi.org/10.1177/2515841420971936
dc.identifier.urihttps://hdl.handle.net/20.500.12511/6083
dc.identifier.volume12
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSAGE Publications Ltd
dc.relation.ispartofTherapeutic Advances in Ophthalmologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectDexamethasone Implantation
dc.subjectDiabetic Macular Edema
dc.subjectOptical Coherence Tomography
dc.subjectRanibizumab
dc.subjectSerous Retinal Detachment
dc.titleEffects of dexamethasone treatment on serous retinal detachment in ranibizumab-resistant diabetic macular edema
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Bayat, Alper Halil-2020.pdf
Boyut:
748.59 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: